Literature DB >> 33965624

Mitochondria-targeted graphene for advanced cancer therapeutics.

Tanveer A Tabish1, Roger J Narayan2.   

Abstract

There have been numerous efforts to develop targeted therapies for treating cancer. The non-specificity of 'classical' cytotoxic chemotherapy drugs and drug resistance remain major challenges in cancer dormancy. Mitochondria-targeted therapy is an alternative strategy for the treatment of numerous cancer types and is heavily dependent on the ability of the anticancer drugs to reach the tumor mitochondria in a safe and selective manner. Over the past two decades, research efforts have provided mechanistic insights into the roles of mitochondria in cancer progression and therapies that specifically target cancer mitochondria. Given that several nanotechnology-driven strategies aimed at therapeutically targeting mitochondrial dysfunction are still in their infancy, this review considers the cross-disciplinary nature of this area and focuses on the design and development of mitochondria-targeted graphene (mitoGRAPH), its immense potential, and future use for selective targeting of cancer mitochondria. This review also provides novel insights into the strategies for preparing mitoGRAPH to destroy the cell powerhouse in a targeted fashion. Targeting mitochondria with graphene may represent an important therapeutic approach that transforms therapeutic interventions. STATEMENT OF SIGNIFICANCE: Mitochondria-targeted therapy represents a major advance for treating several medical conditions. At this time, no nanoparticles (NPs) or nanocarriers are clinically available, which are capable of spatial targeting and controlled delivery of drugs to mitochondria. NPs-based approaches have revolutionized the field of targeted therapy and have demonstrated efficacy for delivering drugs selectively to mitochondria. These NPs show limited results in pre-clinical animal models due to their adverse side effects and inadequate therapeutic outcomes. Over the past decade, graphene has emerged as a potential anticancer agent and has shown great potential in targeting tumor mitochondria in a safe and targeted fashion. This review considers recent advances in the use of mitochondria-targeted graphene (mitoGRAPH) in chemotherapy, photodynamic therapy, photothermal therapy, and combination therapies.
Copyright © 2021 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; Mitochondria; Mitochondria-targeted graphene; Therapy

Year:  2021        PMID: 33965624     DOI: 10.1016/j.actbio.2021.04.054

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   8.947


  9 in total

Review 1.  Advances in Biologically Applicable Graphene-Based 2D Nanomaterials.

Authors:  Josef Jampilek; Katarina Kralova
Journal:  Int J Mol Sci       Date:  2022-06-02       Impact factor: 6.208

Review 2.  Progress of Nanomaterials in Photodynamic Therapy Against Tumor.

Authors:  Lei Chen; Jiahui Huang; Xiaotong Li; Miaoting Huang; Shaoting Zeng; Jiayi Zheng; Shuyi Peng; Shiying Li
Journal:  Front Bioeng Biotechnol       Date:  2022-05-31

3.  Intracellular Amplifiers of Reactive Oxygen Species Affecting Mitochondria as Radiosensitizers.

Authors:  Hong-Gui Xu; Viktor Reshetnikov; Marit Wondrak; Lisa Eckhardt; Leoni A Kunz-Schughart; Christina Janko; Rainer Tietze; Christoph Alexiou; Hannes Borchardt; Achim Aigner; Wenjie Gong; Michael Schmitt; Leopold Sellner; Steffen Daum; Hülya Gizem Özkan; Andriy Mokhir
Journal:  Cancers (Basel)       Date:  2021-12-31       Impact factor: 6.639

4.  Targeting Mitochondrial COX-2 Enhances Chemosensitivity via Drp1-Dependent Remodeling of Mitochondrial Dynamics in Hepatocellular Carcinoma.

Authors:  Lin Che; Jia-Shen Wu; Ze-Bang Du; Yu-Qiao He; Lei Yang; Jin-Xian Lin; Zhao Lei; Xiao-Xuan Chen; Dong-Bei Guo; Wen-Gang Li; Yu-Chun Lin; Zhong-Ning Lin
Journal:  Cancers (Basel)       Date:  2022-02-06       Impact factor: 6.639

5.  Graphene Quantum Dots-Based Electrochemical Biosensing Platform for Early Detection of Acute Myocardial Infarction.

Authors:  Tanveer A Tabish; Hasan Hayat; Aumber Abbas; Roger J Narayan
Journal:  Biosensors (Basel)       Date:  2022-01-28

6.  Receptor-Tyrosine Kinase Inhibitor Ponatinib Inhibits Meningioma Growth In Vitro and In Vivo.

Authors:  Tao Yu; Junguo Cao; Montadar Alaa Eddine; Mahmoud Moustafa; Andreas Mock; Cihan Erkut; Amir Abdollahi; Rolf Warta; Andreas Unterberg; Christel Herold-Mende; Gerhard Jungwirth
Journal:  Cancers (Basel)       Date:  2021-11-24       Impact factor: 6.639

Review 7.  Recent Advancements in Mitochondria-Targeted Nanoparticle Drug Delivery for Cancer Therapy.

Authors:  Jiangsheng Xu; James G Shamul; Elyahb Allie Kwizera; Xiaoming He
Journal:  Nanomaterials (Basel)       Date:  2022-02-23       Impact factor: 5.719

Review 8.  The mechanistic immunosuppressive role of the tumour vasculature and potential nanoparticle-mediated therapeutic strategies.

Authors:  Zakaria Elias Ileiwat; Tanveer A Tabish; Dmitry A Zinovkin; Jale Yuzugulen; Nahid Arghiani; Md Zahidul I Pranjol
Journal:  Front Immunol       Date:  2022-08-15       Impact factor: 8.786

9.  Common methods in mitochondrial research (Review).

Authors:  Yiyuan Yin; Haitao Shen
Journal:  Int J Mol Med       Date:  2022-08-25       Impact factor: 5.314

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.